Abstract 4143772: Genome wide association study meta-analysis of 19,487 individuals with mitral valve prolapse identifies 52 novel genomic regions and highlights pro-fibrosis genes

Introduction: Mitral valve prolapse (MVP) is the most common cause of primary mitral regurgitation and is estimated to affect between 1-3% of the general population. A subset of individuals with MVP develop malignant arrhythmias, often in the context of myocardial fibrosis. The genetics of MVP, and genetic factors explaining why only some individuals with MVP have adverse outcomes, remains poorly understood. Methods: We defined MVP using a combination of claims data and echocardiographic diagnosis across 15 cohorts spanning 5 countries and performed a meta-analysis of genome-wide association studies (GWAS) for MVP including 19,487 MVP cases among 2,247,054 individuals. Causal genes were prioritized using a combination of methods including the identification of variants in active promoters/enhancers using mitral valve ATAC-seq data from an external dataset. To determine whether prioritized genes may be differentially expressed in myocardial fibrosis, we compared single-cell RNA sequencing between fibrosed papillary muscles and normal left ventricular among two individuals with severe MVP. Results: There were 67 unique genome-wide significant (GWS; p<5x10 -8 ) genomic regions, of which 52 were novel. Of these, 38 GWS regions included either missense variants or variants overlapping a promoter active in valve tissue as suggested by mitral valve ATAC-seq data. Pathway analysis of prioritized genes highlighted etiological roles for extracellular matrix and cardiomyocyte biology. 33 prioritized genes were differentially expressed between fibrotic papillary muscle tissue and normal left ventricle, the majority of which were specific to cardiomyocytes. One of these genes, CAMK2D , was also observed as sub-GWS in a recent GWAS of myocardial interstitial fibrosis and has notable pleiotropy for arrhythmia traits including atrial fibrillation and atrioventricular block. Conclusions: We performed the largest GWAS of MVP to-date, discovering 52 novel GWS regions, and prioritized genes relevant to myocardial fibrosis, an important risk factor for adverse outcomes among individuals with MVP.

Authors

Institutions

Publication Details

Journal
Circulation
Published
2024-11-12
DOI
https://doi.org/10.1161/circ.150.suppl_1.4143772
Primary Topic
Cardiac Valve Diseases and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 4143772: Genome wide association study meta-analysis of 19,487 individuals with mitral valve prolapse identifies 52 novel genomic regions and highlights pro-fibrosis genes

Peter W.F. Wilson, Michael Andrew Borger, Erik Abner, Hreinn Stefánsson et al.
Circulation
Cardiac Valve Diseases and Treatments
article

Abstract 4143772: Genome wide association study meta-analysis of 19,487 individuals with mitral valve prolapse identifies 52 novel genomic regions and highlights pro-fibrosis genes

Peter W.F. Wilson, Michael Andrew Borger, Erik Abner, Hreinn Stefánsson, Mengyao Yu, Maja‐Theresa Dieterlen, Russell A. Norris, Matthew L. Huff, Eric Farber‐Eger, Adrien Georges, George Thanassoulis, Gina M. Peloso, Jiwoo Lee, Jordan Morningstar, Daníel F. Guðbjartsson, Pradeep Natarajan, Kelly Cho, Ha My T. Vy, Henning Bundgaard, Amy Kontorovich, Aeron Small, Quinn S. Wells, Nabila Bouatia‐Naji, Daniel James Rader, Patrick T. Ellinor, Andrea Ganna, James C. Engert, Anna Helgadóttir, Hilma Hólm, Takiy-Eddine Berrandou, Michael A. Rosenberg, Christopher R. Gignoux, David Milan, Ta‐Yu Yang
article en

Abstract

Introduction: Mitral valve prolapse (MVP) is the most common cause of primary mitral regurgitation and is estimated to affect between 1-3% of the general population. A subset of individuals with MVP develop malignant arrhythmias, often in the context of myocardial fibrosis. The genetics of MVP, and genetic factors explaining why only some individuals with MVP have adverse outcomes, remains poorly understood. Methods: We defined MVP using a combination of claims data and echocardiographic diagnosis across 15 cohorts spanning 5 countries and performed a meta-analysis of genome-wide association studies (GWAS) for MVP including 19,487 MVP cases among 2,247,054 individuals. Causal genes were prioritized using a combination of methods including the identification of variants in active promoters/enhancers using mitral valve ATAC-seq data from an external dataset. To determine whether prioritized genes may be differentially expressed in myocardial fibrosis, we compared single-cell RNA sequencing between fibrosed papillary muscles and normal left ventricular among two individuals with severe MVP. Results: There were 67 unique genome-wide significant (GWS; p<5x10 -8 ) genomic regions, of which 52 were novel. Of these, 38 GWS regions included either missense variants or variants overlapping a promoter active in valve tissue as suggested by mitral valve ATAC-seq data. Pathway analysis of prioritized genes highlighted etiological roles for extracellular matrix and cardiomyocyte biology. 33 prioritized genes were differentially expressed between fibrotic papillary muscle tissue and normal left ventricle, the majority of which were specific to cardiomyocytes. One of these genes, CAMK2D , was also observed as sub-GWS in a recent GWAS of myocardial interstitial fibrosis and has notable pleiotropy for arrhythmia traits including atrial fibrillation and atrioventricular block. Conclusions: We performed the largest GWAS of MVP to-date, discovering 52 novel GWS regions, and prioritized genes relevant to myocardial fibrosis, an important risk factor for adverse outcomes among individuals with MVP.

CirculationVol. 150(Suppl_1)
Broad Institute (US), Boston University (US), Brigham and Women's Hospital (US), deCODE Genetics (Iceland) (IS), Emory University (US), Medical University of South Carolina (US), Inserm (FR), Aarhus University (DK), Fudan University (CN), VA Boston Healthcare System (US), McGill University Health Centre (CA), Copenhagen University Hospital (DK), Karolinska Institutet (SE), Massachusetts General Hospital (US), Leipzig Heart Institute (DE), Paris Cardiovascular Research Center (FR), McGill University (CA), University of Tartu (EE), Vanderbilt University Medical Center (US), University of Colorado Denver (US), Icahn School of Medicine at Mount Sinai (US)
Partnerships for the goals
Openalex Percentile: Top 62%
Cardiac Valve Diseases and Treatments
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.